Sandra Vazquez
National Institutes of Health(US)National Institute of Allergy and Infectious Diseases(US)
Publications by Year
Research Areas
Mosquito-borne diseases and control, Viral Infections and Vectors, Malaria Research and Control, SARS-CoV-2 and COVID-19 Research, Viral Infections and Outbreaks Research
Most-Cited Works
- → Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial(2022)158 cited
- → Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study(2019)125 cited
- → Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria(2022)115 cited
- → An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults(2023)92 cited
- → Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria(2024)78 cited
- Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS).(1987)
- → Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial(2023)62 cited
- → Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial(2022)40 cited
- → Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial(2022)37 cited
- → Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial(2023)37 cited